News|Articles|November 16, 2026

FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder

Author(s)Leah Kuntz
Listen
0:00 / 0:00

Key Takeaways

  • FDA clearance enables dexmedetomidine sublingual film to be administered outside supervised care for acute agitation in schizophrenia-spectrum and bipolar disorders, expanding treatment into patient/caregiver-managed settings.
  • Phase 3 SERENITY evaluated 1160 agitation episodes in 102 participants, meeting the primary endpoint for at-home safety and tolerability with consistent tolerability during repeat dosing.
SHOW MORE

The FDA has approved dexmedetomidine (Igalmi) sublingual film for at-home use.

The US Food and Drug Administration (FDA) today approved Teva Pharmaceuticals’ dexmedetomidine (Igalmi) sublingual film for at-home use. Now, Igalmi is the first FDA-approved treatment that can be used at home for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.1

“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” said Chris Fox, the executive vice prresident, US Commercial and Head of Innovative Franchise at Teva. “With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it, reflecting Teva’s commitment to improving how care is experienced in everyday life.”

More About the Phase 3 SERENITY Trial

The approval was supported by results of the phase 3 SERENITY Trial, in which Igalmi met its primary endpoint of safety and tolerability in the at-home setting.

In the phase 3 SERENITY At-Home Safety and Tolerability Trial, investigators targeted 1160 agitation episodes in 102 participants with Igalmi. Tolerability remained consistent with repeat dosing over the 12-week study period. The most commonly reported adverse events (≥5% and greater than placebo) were somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia. There were no discontinuations due to tolerability with Igalmi treatment.

“Innovation in neuroscience is about discovering new medicines and also about rethinking when, where and how treatment can be delivered,” said Eric Hughes, MD, PhD, the executive vice president, Global R&D and Chief Medical Officer at Teva. “The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”

Next Steps

Teva acquired Igalmi back on October 27, 2026.2 The application for the approval of Igalmi for at-home use was submitted on January 14, 2026, as a supplemental New Drug Application (sNDA) to the Igalmi NDA for use under the supervision of a health care provider. Teva will announce commercialization plans for IGALMI for at-home use at a later date.

References

1. U.S. FDA approves IGALMI® as first at-home acute treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. News release. November 16, 2026. Accessed November 16, 2026. https://www.tevapharm.com/news-and-media/latest-news/u.s.-fda-approves-igalmi-as-first-at-home-acute-treatment-for-agitation-associated-with-schizophrenia-s

2. Teva acquires worldwide rights to BXCL501, further expanding innovative neuroscience pipeline. News release. October 27, 2026. Accessed November 16, 2026. https://www.tevapharm.com/news-and-media/latest-news/teva-acquires-worldwide-rights-to-bxcl501-further-expanding-innovative-neuroscience-pipeline/


Related to this article